ImpediMed (IPD) Q1 2025 TU earnings summary

Executive summary

• Strategy focuses on achieving breakeven through increased sales, cost management, and clinical execution, with strong sales momentum and expanding payor coverage in oncology.

• New board and executive team, including Dr Parmjot Bains as CEO and Mr McGregor Grant as CFO/COO, have implemented proven sales and marketing processes, resulting in a growing pipeline and improved KPIs.

• Product roadmap for the SOZO Digital Health Platform finalized for board review, with growth initiatives under evaluation.

• Focus remains on converting a robust opportunity pipeline into sales, supported by industry endorsements and expanding reimbursement coverage.

Financial highlights

• SOZO Core Business TCV for the quarter was A$4.8 million, up 40% from A$3.4 million in the previous quarter, with renewals seeing a 19% average price increase.

• Annual Recurring Revenue (ARR) as of 30 June 2024 is A$11.6 million, a 21% year-on-year increase.

• Quarterly revenue was A$2.7 million, with minor sequential fluctuations due to timing and currency effects.

• Net operating cash outflows were A$4.8 million, about 10% above budget due to timing, with cash and equivalents at A$18.6 million.

• FY25 cash expenditure is forecast to be 10% lower than FY24 due to headcount and salary adjustments.

Outlook and guidance

• Q2 will extend Q1's focus: lead generation, sales conversion, private payer coverage expansion, and cost control.

• Net operating cash outflow for Q2 FY25 is forecast to decrease to below A$3.5 million and remain at that level for the year.

• The business is comfortable with its liquidity, forecasting four quarters of cash on hand, and has contingency plans for downside scenarios.

• Product roadmap update and growth outlook to be provided with Q2 FY25 results.